Over the past decade, physicians, patients and policy makers have expressed increasing concern about the high frequency of opioids being prescribed and the association between opioid use and poor outcomes. Rates of opioid prescriptions in the general population rose considerably from the 1990s through 2010, with a plateau in the early 2010s. In 2015, 38%… [Read More]
Search results for: opioid
Clinicians’ Use of ‘Safer’ Opioid-Prescribing Practices Spotty
NEW YORK (Reuters Health)—Many U.S. clinicians aren’t following risk-mitigation practices for opioid prescribing, new findings show. “In response to this national opioid crisis, consensus-based safer opioid prescribing guidelines have been published and state laws regulating opioid prescribing practices have been enacted,” Daniel P. Alford, MD, of Boston University School of Medicine, and colleagues write in… [Read More]
FDA Update: Priority Review for Non-Opioid Treatment & New Warning for Fluoroquinolones
The FDA has granted priority review to a non-opioid, postoperative pain treatment, HTX-011…... [Read More]
Former Insys CEO Pleads Guilty to Opioid Kickback Scheme
BOSTON (Reuters)—The former chief executive of Insys Therapeutics Inc pleaded guilty on Wednesday to participating in a nationwide scheme to bribe doctors to prescribe an addictive opioid medication and has agreed to become a government witness. Michael Babich, who resigned as the Arizona-based drugmaker’s CEO in 2015, pleaded guilty in federal court in Boston to… [Read More]
Annual Meeting Speakers Review Studies Ranging from Opioids to Fibroblasts
CHICAGO—Findings on opioid efficacy, serum urate in osteoarthritis and arthrocentesis headlined the top research of the year discussed in the first half of a session at the 2018 ACR/ARHP Annual Meeting. The second half covered basic science findings, including summaries of new insights into the gender bias in autoimmune diseases, platelet microparticles in scleroderma and… [Read More]
FDA Approves Opioid Treatment
The FDA has approved the use of sublingual sufentanil (Dsuvia) to treat acute pain in adults in a medically supervised setting…... [Read More]
FDA Expands Safety Measures for Immediate Release Opioids
The FDA has expanded the new Opioid Analgesic Risk Evaluation and Mitigation Strategy (REMS) to include immediate release opioids. The program, which also includes extended release and long acting opioids, will provide education to prescribers and healthcare professionals…... [Read More]
Insys to Pay $150 Million to Settle U.S. Opioid Kickback Probe
(Reuters)—Insys Therapeutics said on Wednesday it had reached a deal to pay at least $150 million to resolve a U.S. Justice Department investigation into claims that the drugmaker paid doctors kickbacks to prescribe a powerful opioid medication. The tentative deal announced by the Arizona-based drugmaker marked a major step in Insys’ efforts to resolve an… [Read More]
Ethics Forum: What to Do with the Inherited Opioid Patient?
A 67-year-old man with a recent onset of diffuse muscular pain and stiffness and an erythrocyte sedimentation rate of 55 is referred to you by his family practitioner. He has a history of non-insulin-dependent diabetes mellitus, but no history of headaches or swollen joints. He has chronic back pain, has had two surgeries and was… [Read More]
Recro Pharma’s Non-Opioid Pain Shot Fails to Get Approval from FDA
(Reuters)—Recro Pharma’s IV meloxicam, a non-opioid injection, did not get approval from the U.S. Food and Drug Administration because the agency said the drug’s pain-relieving effect did not meet its expectations. The company said it plans to meet with the FDA to find solutions. Unlike the drug’s oral version, which has been on the market… [Read More]
- 1
- 2
- 3
- …
- 26
- Next Page »